Agios Announces Proposed Offering of Common Stock
November 06 2019 - 4:01PM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it
is offering to sell, subject to market and other conditions, up to
7.5 million shares of its common stock in an underwritten public
offering. Agios also intends to grant the underwriters a 30-day
option to purchase up to an additional 15% of the shares of common
stock sold in the public offering. All of the shares in the
offering are to be sold by Agios. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
Cowen and Company, LLC are acting as joint book-running managers
for the offering.
The shares are being offered by Agios pursuant to an
automatically effective shelf registration statement that has been
filed with the Securities and Exchange Commission (“SEC”). The
offering is being made only by means of a prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement relating to, and describing the
terms of, the offering will be filed with the SEC and will be
available on the SEC’s web site at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering can be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 866-803-9204; Goldman Sachs & Co. LLC, Attn:
Prospectus Department, 200 West Street, New York, New York 10282,
telephone: 866-471-2526, facsimile: 212-902-9316, e-mail:
prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY, 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com, or by telephone at (833)
297-2926. The final terms of the offering will be disclosed in a
final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Agios Pharmaceuticals, Inc.
Agios is focused on discovering and developing novel
investigational medicines to treat cancer and rare genetic diseases
through scientific leadership in the field of cellular metabolism
and adjacent areas of biology. In addition to an active research
and discovery pipeline across both therapeutic areas, Agios has two
approved oncology precision medicines and multiple first-in-class
investigational therapies in clinical and/or preclinical
development. All Agios programs focus on genetically identified
patient populations, leveraging our knowledge of metabolism,
biology and genomics.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, such as those, among others, relating to Agios’ plans to
consummate its proposed public offering. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “would,” “could,” “potential,” “possible,”
“hope” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
related to whether or not Agios will be able to raise capital
through the sale of shares of common stock, the final terms of the
proposed offering, market and other conditions, the satisfaction of
customary closing conditions related to the proposed public
offering and the impact of general economic, industry or political
conditions in the United States or internationally. There can be no
assurance that Agios will be able to complete the proposed public
offering on the anticipated terms, or at all. You should not place
undue reliance on these forward-looking statements. Additional
risks and uncertainties relating to the proposed offering, Agios
and its business can be found under the caption “Risk Factors”
included in Agios’ Quarterly Report on Form 10-Q for the quarter
ended September 30, 2019, Agios’ preliminary prospectus supplement
to be filed with the SEC on November 6, 2019, and other filings
that Agios may make with the SEC in the future. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Agios expressly disclaims any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor & Media Contact: Holly Manning,
617-844-6630 Associate Director, Investor Relations
Holly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024